FLT3LG and melanoma: In a phase 2 trial of participants with resected melanoma, daily administration of Flt3L (CDX-301) for 10 days before administration of DC-targeted vaccines led to expansion of DC subsets and significant enhancement of cellular and humoral responses (40).